










































Fig. 1 Sustained upregulation of
SAMMSON lncRNA expression
in skin melanoma (SKCM) and
uveal melanoma (UVM)
































































































































































































































































* * * * *
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I
Fig. 2 LNA-based ASO3 and ASO11 treatment result in a knock down of SAMMSON expression in conjunctival melanoma
cell line CRMM1 (A) and uveal melanoma cell lines OMM2.3 and 92.1 (B, C).
Fig. 3 LNA-based ASO3 and ASO11 reduce the cell viability (A) and induce apoptosis (B) in multiple uveal


















Fig. 4 Two independent methods to investigate mitochondrial function show a decreased mitochondrial respiration upon SAMMSON knock
down. ASO3 treatment results in an overall decreased oxygen consumption rate (OCR) (A) and significant decreased spare mitochondrial


























































Fig. 6 SAMMSON inhibition (ASO3) as a monotherapy inhibits tumor growth. Combining ASO3 with MEK inhibitor trametinib results in a
further decrease of the tumor growth.
Fig. 5 SAMMSON inhibition (ASO3) in combination with increasing concentrations of the MEK
inhibitor trametinib results in a synergistic decrease in viability in uveal melanoma cell line 92.1
(A) and conjunctival melanoma cell line CRMM1 (B). Drug interaction was calculated using BLISS
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